Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MAP2K4 | P45985 | 11/20 | 0.52 |
| ▸ | MAP2K7 | O14733 | 3/20 | 0.51 |
| ▸ | HTR6 | P50406 | 3/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | HTR7 | P34969 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | ITK | Q08881 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | FADS1 | O60427 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1460974 | 0.91 | ITK (0.59) | MAP2K4MAP2K7ITK | |
| SCHEMBL4011264 | 0.87 | MAPT (0.55) | LMNATP53MAPTMAP2K4MAP2K7 | |
| SCHEMBL4008447 | 0.86 | LMNA (0.54) | LMNATP53MAPTMAP2K4MAP2K7 | |
| SCHEMBL4007759 | 0.86 | LMNA (0.54) | LMNATP53MAPTMAP2K4MAP2K7 | |
| SCHEMBL4015302 | 0.84 | MAP2K4 (0.66) | LMNATP53MAPTMAP2K4MAP2K7 | |
| SCHEMBL4007700 | 0.83 | LMNA (0.57) | LMNATP53MAPTMAP2K4MAP2K7 | |
| SCHEMBL4003137 | 0.82 | TSHR (0.52) | LMNATP53MAPTMAP2K4MAP2K7 | |
| SCHEMBL4007929 | 0.81 | MAP2K4 (0.54) | LMNATP53MAPTMAP2K4HTR6 | |
| SCHEMBL4008915 | 0.80 | NTRK1 (0.52) | LMNATP53MAPTMAP2K4MAP2K7 | |
| SCHEMBL4008270 | 0.79 | MAPT (0.60) | LMNATP53MAPTMAP2K4MAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| CN-100369899-C | Substituted indazoles with anti-cancer activity | AVENTIS PHARMA SA (FR) | 2008-02-20 | — | — | CN | disclosed |
| CN-1642922-A | Substituted indazoles with anti-cancer activity | AVENTIS PHARMA SA (FR) | 2005-07-20 | — | — | CN | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | LMNA 3903/4885TP53 234/4885MAPT 2426/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | LMNA 4186/4885TP53 294/4885MAPT 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.